286 related articles for article (PubMed ID: 38102001)
1. Harnessing the potential of CD40 agonism in cancer therapy.
Zhou Y; Richmond A; Yan C
Cytokine Growth Factor Rev; 2024 Feb; 75():40-56. PubMed ID: 38102001
[TBL] [Abstract][Full Text] [Related]
2. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
3. Agonistic CD40 Antibodies in Cancer Treatment.
Djureinovic D; Wang M; Kluger HM
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804039
[TBL] [Abstract][Full Text] [Related]
4. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
6. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
7. New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5).
Piechutta M; Berghoff AS
ESMO Open; 2019; 4(Suppl 3):e000510. PubMed ID: 31275618
[TBL] [Abstract][Full Text] [Related]
8. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis.
Bugajska U; Georgopoulos NT; Southgate J; Johnson PW; Graber P; Gordon J; Selby PJ; Trejdosiewicz LK
J Natl Cancer Inst; 2002 Sep; 94(18):1381-95. PubMed ID: 12237284
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
[TBL] [Abstract][Full Text] [Related]
10. Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells.
Hillebrand RM; Vogt A; Strassburg CP; Gonzalez-Carmona MA; Schmidt-Wolf IGH
Anticancer Res; 2019 Sep; 39(9):4643-4652. PubMed ID: 31519562
[TBL] [Abstract][Full Text] [Related]
11. XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models.
Wang B; Liu Y; Yuan R; Dou X; Qian N; Pan X; Xu G; Xu Q; Dong B; Yang C; Li H; Wang J; Bai G; Liu L; Gao X
Cancer Immunol Immunother; 2023 Dec; 72(12):4015-4030. PubMed ID: 37863852
[TBL] [Abstract][Full Text] [Related]
12. A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies.
Jian CZ; Lin L; Hsu CL; Chen YH; Hsu C; Tan CT; Ou DL
Drug Discov Today; 2024 Mar; 29(3):103893. PubMed ID: 38272173
[TBL] [Abstract][Full Text] [Related]
13. CD40 activation as potential tool in malignant neoplasms.
Ottaiano A; Pisano C; De Chiara A; Ascierto PA; Botti G; Barletta E; Apice G; Gridelli C; Iaffaioli VR
Tumori; 2002; 88(5):361-6. PubMed ID: 12487551
[TBL] [Abstract][Full Text] [Related]
14. Murine Fibroblastic Reticular Cells From Lymph Node Interact With CD4+ T Cells Through CD40-CD40L.
Nakayama Y; Brinkman CC; Bromberg JS
Transplantation; 2015 Aug; 99(8):1561-7. PubMed ID: 25856408
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.
Tang T; Cheng X; Truong B; Sun L; Yang X; Wang H
Pharmacol Ther; 2021 Mar; 219():107709. PubMed ID: 33091428
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism and function of CD40/CD40L engagement in the immune system.
Elgueta R; Benson MJ; de Vries VC; Wasiuk A; Guo Y; Noelle RJ
Immunol Rev; 2009 May; 229(1):152-72. PubMed ID: 19426221
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
18. CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation.
Elmetwali T; Salman A; Wei W; Hussain SA; Young LS; Palmer DH
Sci Rep; 2020 Jan; 10(1):342. PubMed ID: 31941968
[TBL] [Abstract][Full Text] [Related]
19. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues.
Gruss HJ; Herrmann F; Gattei V; Gloghini A; Pinto A; Carbone A
Leuk Lymphoma; 1997 Feb; 24(5-6):393-422. PubMed ID: 9086433
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab.
Asano R; Nakakido M; Pérez JF; Ise T; Caaveiro JMM; Nagata S; Tsumoto K
Biochem Biophys Res Commun; 2024 Jun; 714():149969. PubMed ID: 38657446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]